AssureCKD Team Publishes Breakthrough Research in Nature Microsystems & Nanoengineering
AssureCKD is a Canadian medical device company developing a lab-equivalent, point-of-care screening platform for chronic kidney disease (CKD), is proud to announce that its technology and research collaborators have been published in Nature Microsystems & Nanoengineering.
The peer-reviewed article, titled “A fully integrated paper-based microfluidic device for low-cost quantitative albumin-to-creatinine ratio (ACR) measurement at the point-of-care”, presents the foundational microfluidic work underpinning AssureCKD’s MATLOC platform. The publication details the development of a compact, low-cost system for rapid and reliable uACR testing, which is essential for early CKD detection and monitoring.
This milestone underscores the scientific rigor and innovation driving AssureCKD’s mission to improve kidney health outcomes through accessible screening and diagnostic tools. The study was led by Dr. Francis Lin and Dr. Claudio Rigatto, two of the platform’s scientific co-founders, alongside researchers from the University of Manitoba and collaborating institutions.
“This publication is a validation of years of translational research and development,” said Harrison Ross, CEO of AssureCKD. “It reinforces our belief that accessible, lab-equivalent diagnostics at the point-of- care can meaningfully shift the trajectory of kidney disease.”
The full article is available online via Nature:
About AssureCKD
AssureCKD is developing MATLOC, a lab-equivalent diagnostic platform designed to screen, diagnose, and monitor chronic kidney disease at the point-of-care. By enabling rapid, accessible, and cost-effective testing in primary care and decentralized settings, AssureCKD aims to increase screening rates and facilitate earlier intervention, ultimately improving outcomes and reducing expensive healthcare costs.
If you are experiencing any of these symptoms alongside your comorbidities, please consider asking your doctor for further testing, as eGFR and uACR testing is the first step towards diagnosis and treatment.